Results 51 to 60 of about 119,989 (312)

Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells [PDF]

, 2016
Two major barriers to cancer immunotherapy include tumor-induced immune suppression mediated by myeloid-derived suppressor cells and poor immunogenicity of the tumor-expressing self-antigens.
Bear, Harry D., Graham, Laura, Idowu, Michael O., Keim, Rebecca, Manjili, Masoud H., Payne, Kyle K., Toor, Amir A., Wan, Wen, Wang, Xiang-Yang   +8 more
core   +2 more sources

Chimeric Antigen Receptor T Cell Therapy in Hematology

Turkish Journal of Hematology, 2015
It is well demonstrated that the immune system can control and eliminate cancer cells. Immune-mediated elimination of tumor cells has been discovered and is the basis of both cancer vaccines and cellular therapies including hematopoietic stem cell ...
Pınar Ataca, Önder Arslan
doaj   +1 more source

Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. [PDF]

, 2014
The majority of chimeric antigen receptor (CAR) T-cell research has focused on attacking cancer cells. Here, we show that targeting the tumor-promoting, nontransformed stromal cells using CAR T cells may offer several advantages.
Albelda, Steven M., Antzis, Michael, Cotner, Cody E., Durham, Amy C., Johnson, Laura A., June, Carl H., Kapoor, Veena, Lo, Albert, Majumdar, Rajrupa S., Puré, Ellen, Scholler, John, Solomides, MD, Charalambos C., Sun, Jing, Wang, Liang-Chuan S.   +13 more
core   +2 more sources

Autotransplantation of T-lymphocytes as a tool for antigen-specific immunotherapy of oncological diseases

Вестник трансплантологии и искусственных органов, 2018
Autotransplantation of immune cells to induce immunological rejection of tumors can be a useful approach in tumor treatment. Despite the low efficiency of this  approach demonstrated in the past, the active development of cell technologies and  genetic ...
A. Yu. Lupatov, P. A. Karalkin, A. A. Boyko, K. N. Yarygin   +3 more
doaj   +1 more source

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

Molecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago‐Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant   +14 more
wiley   +1 more source

Molecular and functional profiling unravels targetable vulnerabilities in colorectal cancer

Molecular Oncology, EarlyView.
We used whole exome and RNA‐sequencing to profile divergent genomic and transcriptomic landscapes of microsatellite stable (MSS) and microsatellite instable (MSI) colorectal cancer. Alterations were classified using a computational score for integrative cancer variant annotation and prioritization.
Efstathios‐Iason Vlachavas, Konstantinos Voutetakis, Vivian Kosmidou, Spyridon Tsikalakis, Spyridon Roditis, Konstantinos Pateas, Ryangguk Kim, Kymberleigh Pagel, Stephan Wolf, Gregor Warsow, Antonia Dimitrakopoulou‐Strauss, Georgios N. Zografos, Alexander Pintzas, Johannes Betge, Olga Papadodima, Stefan Wiemann   +15 more
wiley   +1 more source

Immune evasion in cancer: mechanistic basis and therapeutic strategies [PDF]

, 2015
Cancer immune evasion is a major stumbling block in designing effective anticancer therapeutic strategies. Although considerable progress has been made in understanding how cancers evade destructive immunity, measures to counteract tumor escape have not ...
Amin, Amr, Aquilano, Katia, Ashraf, S. Salman, Azmi, Asfar S., Bhakta, Dipita, Bilsland, Alan, Boosani, Chandra S., Chen, Sophie, Choi, Beom K., Ciriolo, Maria Rosa, Decker, William K., Elkord, Eyad, Fujii, Hiromasa, Georgakilas, Alexandros G., Guha, Gunjan, Halicka, Dorota, Helferich, William G., Honoki, Kanya, Keith, W. Nicol, Kumara, H.M.C. Shantha, Kwona, Byoung S., Lichtor, Terry, Mohammed, Sulma I., Nowsheen, Somaira, Pawelec, Graham, Ryan, Elizabeth P., Signori, Emanuela, Stagg, John, Talib, Wamidh H., Vinay, Dass S., Whelan, Richard L., Yang, Xujuan   +31 more
core   +1 more source

Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting

Nature Communications, 2021
KRAS is commonly mutated at codon 12 in several cancer types, offering a unique opportunity for the development of neoantigen-targeted immunotherapy. Here the authors present a pipeline for the prediction, identification and validation of HLA class-I ...
Adham S. Bear, Tatiana Blanchard, Joseph Cesare, Michael J. Ford, Lee P. Richman, Chong Xu, Miren L. Baroja, Sarah McCuaig, Christina Costeas, Khatuna Gabunia, John Scholler, Avery D. Posey, Mark H. O’Hara, Anze Smole, Daniel J. Powell, Benjamin A. Garcia, Robert H. Vonderheide, Gerald P. Linette, Beatriz M. Carreno   +18 more
doaj   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

Immunotherapy of invasive fungal infection in hematopoietic stem cell transplant recipients [PDF]

, 2013
Despite the availability of new antifungal compounds, invasive fungal infection remains a significant cause of morbidity and mortality in children and adults undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Allogeneic HSCT recipients
Klingebiel, Thomas, Lehrnbecher, Thomas, Schmidt, Stanislaw, Tramsen, Lars   +3 more
core   +2 more sources